CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

200403Orig1s000

MICROBIOLOGY REVIEW(S)

Product Quality Microbiology Review

24 January 2011

NDA: 200-403/N000

Drug Product Name
Proprietary: NA
Non-proprietary: Hydromorphone Hydrochloride Injection USP

Review Number: 1

Dates of Submission(s) Covered by this Review

Submit	Received	Review Request	Assigned to Reviewer
29 APR 2010	30 APR 2010	17 MAY 2010	25 MAY 2010
18 OCT 2010 (SD 05)	18 OCT 2010	NA	NA
28 OCT 2010 (SD 07)	29 OCT 2010	NA	NA
23 DEC 2010 (SD 11)	23 DEC 2010	NA	NA
05 JAN 2011 (SD 12)	06 JAN 2011	NA	NA

Submission History (for amendments only) – NA

Applicant/Sponsor
Name: Hospira
Address: 275 North Field Dr.
Dept 0389 Bldg. H2-2
Lake Forest, IL 60045

Representative: Jennifer Hefele, Ph.D
Program Manager, Global Regulatory Affairs
Telephone: (224) 212-4889

Name of Reviewer: Denise A. Miller

Conclusion: Approve

Product Quality Microbiology Data Sheet

A. 1. TYPE OF SUBMISSION: Original

2. SUBMISSION PROVIDES FOR: (b) (4) manufacturing of hydromorphone hydrochloride Injection, USP

3. MANUFACTURING SITE:
Hospira, Inc.
1776 N. Centennial Drive
McPherson KS 67460

Registration # 1925262

4. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:

- Dosage Form: sterile solution for injection
- Route of Administration: intravenous, intramuscular or subcutaneous
- Strength/Potency: 1, 2, and 4 mg/mL

5. METHOD(S) OF STERILIZATION: (b) (4)

6. PHARMACOLOGICAL CATEGORY: Opioid analgesic, Schedule II

B. SUPPORTING/RELATED DOCUMENTS: NA

C. REMARKS:
1) Application is in e-CTD format
2) This is an unapproved marketed drug (b) (4)
3) An Information Request (IR) was sent to the sponsor on 06 OCT 2010 with an e-mail response received on 11 OCT 2010. The response was then submitted into DARRTS on 18 OCT 2010 under supporting document (SD) 05. The response was deficient in that one of the reports received in the response contained pages from an unrelated report and was missing pages. A corrected report was sent on 28 OCT 2010 (SD 07).
4) A second IR was sent on 17 DEC 2010 for which a response was received on 23 DEC 2010 (SD 11).
5) A third IR was sent on 03 JAN 2011 for which a response was received on 06 JAN 2011 (SD 12).

filename: N200403N000R1.doc

Executive Summary

I. Recommendations

A. Recommendation on Approvability - Recommend to approve from a quality microbiology standpoint.

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable - NA

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology –The manufacture includes (b) (4)

B. Brief Description of Microbiology Deficiencies – None

C. Assessment of Risk Due to Microbiology Deficiencies - NA

III. Administrative

A. Reviewer's Signature _____
Denise A. Miller, Microbiologist

B. Endorsement Block _____
James L. McVey, Team Leader

C. CC Block
N/A

34 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

---

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DENISE A MILLER
01/24/2011

JAMES L MCVEY
01/25/2011
I concur.

PRODUCT QUALITY MICROBIOLOGY FILING CHECKLIST

NDA Number:200-403 **Applicant:** Hospira **Letter Date:** 29 April 2010

Drug Name: Hydromorphone Hydrochloride Injection **NDA Type:** 505 (b)(2) **Stamp Date:** 30 April 2010

The following are necessary to initiate a review of the NDA application:

	Content Parameter	Yes	No	Comments
1	Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?	√		e-CDT format
2	Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?	√		EM program Facility floor plans Manufacturing process
3	Has the applicant submitted protocols and results of validation studies concerning microbiological control processes used in the manufacture of the drug product?	√		(b) (4) [redacted]
4	Are any study reports or published articles in a foreign language? If yes, has the translated version been included in the submission for review?		√	
5	Has the applicant submitted preservative effectiveness studies (if applicable) and container-closure integrity studies?	√		Preservative eff. NA CC studies were submitted
6	Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?	√		Sterility and endotoxin included
7	Has the applicant submitted the results of analytical method verification studies?	√		E&I studies B&F studies
8	Has the applicant submitted all special/critical studies/data requested during pre-submission meetings and/or discussions?	NA		
9	Is this NDA fileable? If not, then describe why.	Yes		

Additional Comments: NA

Denise A. Miller, Microbiologist Date

Stephen E. Langille, Ph.D. Date

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-200403	ORIG-1	HOSPIRA INC	Hydromorphone Hydrochloride Injection 1,2,4 mg/mL

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DENISE A MILLER
06/04/2010

STEPHEN E LANGILLE
06/04/2010